Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

In a report released today, Gregory Renza from RBC Capital reiterated a Buy rating on Verastem (VSTM – Research Report), with a price target of ...

TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase I for Unspecified Neurologic Disorders.

According to latest analysis by Report Ocean, the global antibody drugs market is poised to grow by USD 91 billion during 2022-2028, progressing at a CAGR of 9.7% during the forecast period. Request ...

Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Hypopharyngeal Cancer.

Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...

Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice ...